Author Archive
INTERVIEW: American Creek #AMK.ca Discusses Potential Quantity and Grade of Gold Mineralization (1.8 – 1.9 Million Ounces @ 1.12 – 1.35 G/t) at the Treaty Creek $SEA $SA $SKE.ca $TUD.ca $PVG $MRO.ca
INTERVIEW: CFN Interviews Ryan Brown about $NBUD.ca Strategy $TLRY
North Bud Farms Inc (C.NBUD) CEO Ryan Brown met with CannabisFN Media to lay out and explain the company’s strategic and future direction as the industry moves closer into Legalization 2.0.
The company is focusing on a sustainable production and procurement of cannabinoids while pursuing a license under the Access To Cannabis for Medical Purpose Regulations (ACMPR).
AGORACOM Welcomes North Bud Farms Inc. $NBUD.ca Focusing On Sustainable Low Cost, High Quality Cannabinoid Production
WHY NORTH BUD FARMS INC?
- Canadian regulatory door for CIP (Cannabinoid Infused Products) is opening in 2019
As shown in other legal jurisdictions (Colorado, Washington, Nevada, California) - Infused products sector has become the highest margin segment of the industry
- Positioned to be a raw input producer for this space
- Currently working with multiple food, beverage and science companies to provide safe standardized cannabinoid infused raw inputs for large scale GMP manufacturing of products
THE OPPORTUNITY
- Acquired late stage ACMPR applicant GrowPros
MMP from Tetra Bio-Pharma (TSXV: TBP) - GrowPros MMP application was submitted in November 2014 and is currently in the ‘Confirmation of Readiness’ stage.
- Phase 1 is located on 95 acres of agricultural farmland in Low, Québec.
- Option exists to acquire more land if needed
- Facility will focus on GMP (higher production grade) pharma-grade cultivation and food-grade extracted inputs
LOCATION
SITE DETAILS: LOW COST INFRASTRUCTURE
POSITIONED FOR LEGALIZATION 2.0
- First mover advantage often becomes first-mover disadvantage
Examples: AOL, Netscape, Yahoo, BlackBerry - Second mover advantage: clearer picture of market and competition
Examples: Google, Facebook, Amazon, Apple, NORTHBUD
STRATEGIC VERTICALS
Pharma Development
- North Bud will focus on GMP standardized production to be used by our pharma commercialization partners i.e. Tetra Bio-Pharma We will focus on securing unique strains containing high amounts of specific cannabinoids not typically found in recreational cannabis.
Food Grade Inputs
-
- Using our licensed encapsulation technology we will
engage existing food and beverage companies looking
to develop product lines containing cannabis.
- Using our licensed encapsulation technology we will
ReadyUp raises $2 million to manage #Esports teams and help players improve $GMBL $ATVI $TTWO $GAME $EPY.ca $TCEHF $Game.ca $EPY.ca
- ReadyUp, a platform for player connection and team management for gaming and esports, has raised $2 million in funding from game-savvy investors.
- The combined company has 11 people in San Francisco, and they will focus on a few different missions related to esports, said Alemania, in an interview with GamesBeat.
North Bud Farms $NBUD.ca Closes $944,500 Private Placement $AERO $CBDS $CGRW $APH.ca $GBLX
- Announced the closing of a non-brokered private placement offering consisting of 3,778,000 units, at a price of $0.25 per Unit, for gross proceeds of $944,500.
- Each Unit is comprised of one Common Share and one-half (1/2) of a Common Share purchase warrant, with each whole warrant entitling the holder hereof to acquire one additional Common Share at a price of $0.40 per Common Share until September 20, 2020
TORONTO, Sept. 20, 2018 – North Bud Farms Inc. (CSE: NBUD) (the “Corporation“), is pleased to announce the closing of a non-brokered private placement offering (the “Private Placement“) consisting of 3,778,000 units (“Units“), at a price of $0.25 per Unit, for gross proceeds of $944,500. Each Unit is comprised of one Common Share and one-half (1/2) of a Common Share purchase warrant, with each whole warrant entitling the holder hereof to acquire one additional Common Share at a price of $0.40 per Common Share until September 20, 2020. No fees or commissions were paid in connection with the Private Placement. The terms of the Private Placement are the same as the Corporation’s previously-completed private placement (July 25, 2018, as disclosed in the Corporation’s prospectus dated August 21, 2018).
Mr. Andre Audet, the Chairman of the Corporation, participated in the Private Placement by subscribing for 200,000 Units (the “Insider’s Participation“).  The Insider’s Participation is exempt from the formal valuation and minority shareholder approval requirements provided under Multilateral Instrument 61-101 Protection of Minority Holders in Special Transactions (“MI 61-101“) in accordance with sections 5.5(a) and 5.7(a) of MI 61-101. The exemption is based on the fact that neither the fair market value of the Insider’s Participation nor the consideration paid by such insider exceeds 25% of the Corporation’s market capitalization. The Corporation did not file a material change report at least 21 days prior to the completion of the Private Placement since the Insider’s Participation was not determined at that moment.
The Corporation intends to use the proceeds of the Private Placement to continue to advance the license application of GrowPros MMP Inc. under the Access to Cannabis for Medical Purposes Regulations (ACMPR) and for general working capital purposes.
The securities acquired by the subscribers are subject to a hold period of four months plus one day from the closing date, ending on January 21, 2019, except as permitted by applicable securities legislation.
About North Bud Farms Inc.
North Bud Farms Inc., through its wholly-owned subsidiary GrowPros MMP Inc. which was acquired from Tetra Bio-Pharma Inc. (TSX-V: TBP) (OTCQB: TBPMF) in February 2018, is pursuing a license under the Access to Cannabis for Medical Purposes Regulations (ACMPR).  North Bud Farms will be constructing a state-of-the-art purpose-built cannabis production facility located on 95 acres of Agricultural Land in Low, Quebec. North Bud Farms will be focused on Pharmaceutical and Food Grade cannabinoid production in preparation for the legalization of edibles and ingestible products scheduled for October 2019.
For more information visit: www.northbud.com
Neither the Canadian Securities Exchange (the “CSEâ€) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statementsâ€), including those identified by the expressions “anticipateâ€, “believeâ€, “planâ€, “estimateâ€, “expectâ€, “intendâ€, “mayâ€, “should†and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward- looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such risks and uncertainties include, among others, the risk factors included in North Bud Farm’s final long form prospectus dated August 21, 2018 which is available under the issuer’s SEDAR profile at www.sedar.com.
FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
[email protected]
Tetra Bio-Pharma $TBP.ca Announces Significant Progress on Storz & Bickel Co-Development in Treating #Fibromyalgia $AERO $CBDS $CGRW $APH.ca $GBLX
- Made significant progress in its co-development partnership with Storz & Bickel
- The study protocol has received approval from the Independent Ethics Board (IRB Services) and was recently submitted for review to Health Canada
ORLEANS, Ontario, Sept. 20, 2018 — Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), has made significant progress in its co-development partnership with Storz & Bickel. The study protocol has received approval from the Independent Ethics Board (IRB Services) and was recently submitted for review to Health Canada.  In addition, Tetra Bio-Pharma expects to complete the identification of every compound in the PPP001 vapor generated by the Mighty Medic vaporizer later this month. Tetra intends on initiating a Phase 1 clinical study in healthy volunteers to determine the safety and pharmacokinetics of its vaporized PPP001 drug later this year.
This clinical data and vapor compound identification will allow Tetra to bridge to its existing and future clinical data of the Phase 3. The bridge will provide a significantly reduced time to market and reduced development cost for the commercialization of PPP001 as a treatment for fibromyalgia.
“The Independent Ethics Board approval represents a major step forward prior to obtaining approval from Health Canada and the clinical study will allow Tetra to accelerate bringing PPP001 for fibromyalgia patients,†stated Dr. Guy Chamberland, Ph.D., Interim CEO and CSO at Tetra Bio-Pharma. “We are very confident in Tetra’s strategy to become a global leader in the development of cannabinoid derived prescription and natural health products.â€
About Storz & Bickel
STORZ & BICKELÂ built the first factory in the world for the manufacture of medical herbal vaporizers in Tuttlingen, Germany, a town with almost 500 medical device manufacturers. Tuttlingen is reputed to be the center of medical technology, where the first factory to produce surgical instruments was established more than 150 years ago.
About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the approval of PPP001, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]
Media Contact
Energi PR
Carol Levine
514-288-8500 ext. 226
[email protected]
Stephanie Engel
416-425-9143 ext. 209
[email protected]
CLIENT FEATURE: Star Navigation $SNA.ca Real-Time Flight Tracking and Monitoring Technology
STAR-A.D.S.®
- On-board real-time monitoring and data analysis system that provides a “virtual window into an aircraft”
- As cost-effective air to ground communication system that automatically and securely transmits flight data and incident alerts.
- Continuously monitors selected avionics systems on the aircraft from power-on to power-off, instantly analyzes the data, and transmits selected data and any incident alerts, via satellite to the operator.
- Acts as an early warning system, detecting the earliest signs of potential problems
- Performs these functions in “real-time” providing essential safety monitoring to the benefit of passengers, aircraft personnel, and ground crew
- Applications include: Commercial Airlines, Helicopters, Business Aircraft, Assist Search and Rescue by providing last transmitted location
- Recent applications: Emergency Medical Services (airborne and ground vehicles), Land vehicles
CHECK OUT RECENT INTERVIEW
FULL DISCLOSURE: Star Navigation Systems Group Ltd. is an advertising client of AGORA Internet Relations Corp.
#Esports: #Mastercard $MA comes on board as global sponsor for League of Legends #LOL in multi-year deal $GMBL $ATVI $TTWO $GAME $EPY.ca $TCEHF $Game.ca $EPY.ca
- Mastercard announced a multi-year global sponsorship deal with the popular League of Legends eSports title on Wednesday (Sept 19),
- The company’s first such tie-up with an eSports partner
- League of Legends is one of the world’s most widely played and followed eSports games, with about 100 million unique monthly users and its most-watched match pulling in over 80 million live unique viewers
SINGAPORE – Mastercard announced a multi-year global sponsorship deal with the popular League of Legends eSports title on Wednesday (Sept 19), the company’s first such tie-up with an eSports partner.
League of Legends is one of the world’s most widely played and followed eSports games, with about 100 million unique monthly users and its most-watched match pulling in over 80 million live unique viewers.
Mastercard is also League of Legends parent company Riot Games’ first global sponsor. There are about 380 million eSports fans worldwide, according to market researcher Newzoo.
The deal will see Mastercard work with Riot to offer live-event activations and fan experiences across three major annual League of Legends tournaments: the Mid-Season Invitational, the All-Star Event, and the World Championship.
“eSports is a phenomenon that continues to grow in popularity, with fans that can rival those at any major sporting event in their enthusiasm and energy,” said Raja Rajamannar, Mastercard’s chief marketing and communications officer.
“This deal made a lot of sense for us. We’re a global brand and League of Legends is a global phenomenon so the scale is there. In-game purchases are a big part of eSports, and we are a payment solutions company.”
Rajamannar declined to reveal the exact value of the deal but said it was “very comparable” to Mastercard’s other global sponsorships in music and traditional sport with partners like the Grammy Awards and golf’s British Open, one of the sport’s four Major tournaments.
“We’re thrilled to team up with Mastercard on this ground-breaking partnership that will provide meaningful and long-term value to our fans,” said Naz Aletaha, head of eSports partnerships at Riot Games. “Mastercard is among the first of world-class brands to take such a big step into eSports at the global level, and we’re proud to have them support League of Legends eSports events alongside their other premier sports and entertainment sponsorships.”
Fan engagement efforts are set to kick off immediately in the South Korean, Chinese and Taiwanese markets ahead of the 2018 League of Legends World Championships in Seoul next month.
The first experiences available on Mastercard’s Priceless platform include the opportunity to watch a game at the championships with a pro player from VIP seats and behind-the-scenes tours of rehearsals.
Mastercard is also planning to launch a co-branded League of Legends credit card early next year.
Said Rajamannar: “We took two years to fully understand this space because we wanted to be clear how the consumers think. And what we found out is that they want brands to be authentic, organic and creative. So this collaboration is not just about how many cards we must sell but a long-term effort to engage consumers.”
Source: https://www.straitstimes.com/sport/esports-mastercard-comes-on-board-as-global-sponsor-for-league-of-legends-in-multi-year-deal
North Bud $NBUD.ca Farms to Begin Trading on the Canadian Securities Exchange
- will commence trading on the Canadian Securities Exchange at the opening of the market on Thursday, September 20, 2018 under the stock symbol NBUD
TORONTO, Sept. 19, 2018 — North Bud Farms Inc. (“NORTHBUD” or the “Company“) is pleased to announce that its common shares will commence trading on the Canadian Securities Exchange (“CSEâ€) at the opening of the market on Thursday, September 20, 2018 under the stock symbol “NBUDâ€.
“We are proud to achieve this milestone in advance of the historic legalization of Cannabis in Canada on October 17, 2018 and less than 10 months since the Company’s inception which is a testament to the dedication and execution of our experienced management team,†said Ryan Brown, Founder and CEO of North Bud Farms.
Concurrently with the CSE listing, the Company also announces that the board of directors has authorized the grant of 5,100,000 incentive stock options to certain of its directors, officers, employees and consultants. Each such option entitles the holder to acquire one common share for a period of 5 years at an exercise price of $0.25 per common share.
About North Bud Farms Inc.
North Bud Farms Inc., through its wholly-owned subsidiary GrowPros MMP Inc. which was acquired from Tetra Bio-Pharma Inc. (TSX-V: TBP) (OTCQB: TBPMF) in February 2018, is pursuing a license under the Access to Cannabis for Medical Purposes Regulations (ACMPR).  North Bud Farms will be constructing a state-of-the-art purpose-built cannabis production facility located on 95 acres of Agricultural Land in Low, Quebec. North Bud Farms will be focused on Pharmaceutical and Food Grade cannabinoid production in preparation for the legalization of edibles and ingestible products scheduled for October 2019.
For more information visit: www.northbud.com
Neither the Canadian Securities Exchange (the “CSEâ€) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statementsâ€), including those identified by the expressions “anticipateâ€, “believeâ€, “planâ€, “estimateâ€, “expectâ€, “intendâ€, “mayâ€, “should†and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward- looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such risks and uncertainties include, among others, the risk factors included in North Bud Farms’ final long form prospectus dated August 21, 2018 which is available under the issuer’s SEDAR profile at www.sedar.com.
FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
[email protected]
Monarques Gold $MQR.ca Starts Diamond Drilling Program on its McKenzie Break Property $GDX.ca $ECR.ca $MZZ.ca $QMX.ca $IMG.ca $IAG $MUX
- Goal is to increase the 165,608-ounce pit-constrained/underground gold resource
- Announced the start of a new 8,350-metre diamond drilling program on its wholly-owned McKenzie Break gold property
- located 25 kilometres north of Val-d’Or, near Monarques’ Camflo and Beacon mills.
- Drilling started on September 13 with one drill, and a second drill will be added as the work progresses
MONTREAL, Sept. 18, 2018 – MONARQUES GOLD CORPORATION (“Monarques”, “Monarques Gold” or the “Corporation”) (TSXV:MQR) (OTCMKTS:MRQRF) (FRANKFURT:MR7) is pleased to announce the start of a new 8,350-metre diamond drilling program on its wholly-owned McKenzie Break gold property, located 25 kilometres north of Val-d’Or, near Monarques’ Camflo and Beacon mills. Drilling started on September 13 with one drill, and a second drill will be added as the work progresses.
McKenzie Break is a high-grade, multiple-narrow-vein gold deposit hosted in the dioritic Pascalis batholith and underlain by porphyritic diorite and mafic and felsic volcanic rocks. On June 14, 2018, the Corporation reported an NI 43-101 pit-constrained resource of 48,133 ounces in the Indicated category and 14,897 ounces in the Inferred category on the property, as well as an underground resource of 53,448 ounces in the Indicated category and 49,130 ounces in the Inferred category, for a total of 165,608 ounces of gold (see press release dated June 14, 2018).
Historical drilling on the property totals 258 holes and 37,750 metres of core, most of which targeted the Green and Orange zones. The average length of the holes was only 150 metres. The current 39-hole drilling program will consist of holes 150 to 350 metres long to test the property’s potential at depth below the known lenses and on the periphery of the Green and Orange zones (see projected drilling map). The peripheral holes represent infill drilling in areas where information is missing, and could lead to an increase in the size of the planned open pit.
“The McKenzie Break property has great exploration potential,” said Jean-Marc Lacoste, President and Chief Executive Officer of Monarques. “It has the advantages of being high grade at depth and easily accessible, as the average overburden thickness is only 5 metres, meaning that we could put the project into production relatively quickly. The program is aimed at increasing the property’s pit-constrained resource and exploring its potential at depth.”
The technical and scientific content of this press release has been reviewed and approved by Ronald G. Leber, P.Geo., the Corporation’s qualified person under National Instrument 43-101.
ABOUT MONARQUES GOLD CORPORATION
Monarques Gold Corporation (TSXV:MQR) is an emerging gold mining company focused on pursuing growth through its large portfolio of high-quality projects in the Abitibi mining camp in Quebec, Canada. The Corporation currently owns close to 300 km² of gold properties (see map), including the Wasamac deposit (measured and indicated resource of 2.6 million ounces of gold), the Beaufor Mine, the Croinor Gold (see video), McKenzie Break and Swanson advanced projects and the Camflo and Beacon mills, as well as five promising exploration projects. It also offers custom milling services out of its 1,600 tonne-per-day Camflo mill.
Forward-Looking Statements
The forward-looking statements in this press release involve known and unknown risks, uncertainties and other factors that may cause Monarques’ actual results, performance and achievements to be materially different from the results, performance or achievements expressed or implied therein. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
View original content to download multimedia:http://www.prnewswire.com/news-releases/monarques-gold-starts-diamond-drilling-program-on-its-mckenzie-break-property-300714587.html
SOURCE Monarques Gold Corporation
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2018/18/c2592.html
Jean-Marc Lacoste, President and Chief Executive Officer, 1-888-994-4465, [email protected], www.monarquesgold.com; Elisabeth Tremblay, Senior Geologist – Communications Specialist, 1-888-994-4465, [email protected], www.monarquesgold.comCopyright CNW Group 2018